BOSTON, Massachusetts, May 1 /PRNewswire/ -- Sidec announces the first Protein Tomography(TM) Award at Sidec's Executive Forum at PEGS. This Award is set up to enable research groups in the biopharmaceutical industry, who have not yet collaborated with Sidec on a Protein Tomography(TM) study, to get acquainted with Sidec's groundbreaking technology successfully used in cancer drug research.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/294289 )
Sidec announced today the first Protein Tomography(TM) Award. The winning project will obtain a Protein Tomography(TM) collaboration financed by Sidec. This announcement was made at Sidec's Executive Forum during the fourth Annual PEGS meeting organized by CHI.
The use of Protein Tomography(TM) to answer questions related to therapeutic antibody development was presented at Sidec's Executive Forum. Berkley Lynch, previously Principal Investigator at UCB, spoke about the use of Protein Tomography(TM) to Image the Synaptic Vesicle of protein 2A in situ and Jose R. Casas-Finet, Director, R&D and Medical Biochemistry, MedImmune showed how antibody conformations and interactions can be studied by Protein Tomography(TM). At the Forum, Wim, K. Bleeker, Director Translational Research & Pharmacology at Genmab presented the modes of action of HuMax-EGFr (zalutumumab) published in PNAS April 22nd and how this was determined together with Sidec using Protein Tomography(TM).
Finally, Kathleen Madden Williams, PhD, JD Edwards Agnell Palmer & Dodge LLP discussed the ever-narrowing tunnel that present day patent protection on antibodies has entered and whether there is a gold standard by which antibodies are distinguishable from one another thereby to enable more meaningful patent protection.
"During PEGS it became obvious that studying molecular mechanisms is indeed a crucial step in antibody development. Even for some of the best studied anti cancer drug targets, such as CD20, a fundamental understanding of the drug mechanisms is still lacking. Hence, Sidec's Protein Tomography(TM) Award fills an important role in encouraging research groups in the biopharmaceutical industry to try a new avenue, such as Protein Tomography(TM), to increase their chances of success" says Hans Johansson CEO at Sidec AB.
Sidec studies molecular interactions in situ and in vitro using its proprietary technology Protein Tomography(TM). Sidec AB offers collaborative research projects to the biopharmaceutical industry that reveal unique information to prioritize the most promising therapeutic antibody and to locate the antibody binding epitope.
SOURCE Sidec AB